ASND
Ascendis Pharma AS
NASDAQ: ASND · HEALTHCARE · BIOTECHNOLOGY
$220.28
-0.81% today
Updated 2026-04-29
Market cap
$13.61B
P/E ratio
—
P/S ratio
18.90x
EPS (TTM)
$-4.40
Dividend yield
—
52W range
$151 – $251
Volume
0.7M
Ascendis Pharma AS (ASND) Financial statements
SEC filings — annual and quarterly data.
Income statement — annual
| Item | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $15.58M | $20.41M | $13.98M | $8.12M | $4.61M | $1.53M | $10.58M | $13.38M | $6.95M | $7.78M | $51.17M | $266.72M | $363.64M | $691.71M |
| Revenue growth (YoY) | — | +31.0% | -31.5% | -41.9% | -43.3% | -66.8% | +591.6% | +26.4% | -48.0% | +11.9% | +557.9% | +421.2% | +36.3% | +90.2% |
| Cost of revenue | — | $0.00 | $37.28M | $35051.69T | $6.64T | $1000000.00T | $0.00 | $0.00 | $0.00 | $3.52M | $12.14M | $44.40M | $44.26M | $103.18M |
| Gross profit | $15.58M | $20.41M | $13.98M | $8.12M | $4.61M | $1.53M | $10.58M | $13.38M | $6.95M | $4.25M | $39.04M | $222.32M | $319.38M | $588.53M |
| Gross margin | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 54.7% | 76.3% | 83.4% | 87.8% | 85.1% |
| R&D | $11.38M | $12.71M | $19.70M | $40.53M | $66.02M | $99.59M | $140.28M | $191.62M | $260.90M | $295.87M | $379.62M | $413.45M | $307.00M | $283.50M |
| SG&A | $2.69M | $2.42M | $6.27M | $9.41M | $11.50M | $13.48M | $25.06M | $48.47M | $76.67M | $160.18M | $215.85M | $258.79M | $284.55M | $448.04M |
| Operating income | $1.51M | $5.28M | $-11.99M | $-41.83M | $-72.92M | $-111.54M | $-154.76M | $-226.72M | $-330.62M | $-451.79M | $-561.81M | $-455.54M | $-278.76M | $-130.89M |
| Operating margin | 9.7% | 25.9% | -85.7% | -515.2% | -1583.2% | -7290.3% | -1462.6% | -1695.1% | -4755.1% | -5808.6% | -1097.9% | -170.8% | -76.7% | -18.9% |
| EBITDA | $1.73M | $5.68M | $-11.48M | $-33.01M | $-72.12M | $-109.88M | $-150.18M | $-210.36M | $-407.81M | $-364.64M | $-529.18M | $-411.17M | $-290.02M | $-113.90M |
| EBITDA margin | 11.1% | 27.9% | -82.1% | -406.6% | -1565.8% | -7182.0% | -1419.3% | -1572.8% | -5865.2% | -4688.1% | -1034.1% | -154.2% | -79.8% | -16.5% |
| EBIT | $1.30M | $5.28M | $-11.99M | $-33.57M | $-72.83M | $-110.57M | $-151.09M | $-217.03M | $-417.26M | $-380.03M | $-546.69M | $-430.08M | $-307.74M | $-130.89M |
| Interest expense | $20000.00 | $8000.00 | $16000.00 | $6000.00 | $5000.00 | $97000.00 | $127000.00 | $1.22M | $1.92M | $3.91M | $30.68M | $44.06M | $65.50M | $77.46M |
| Income tax | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Effective tax rate | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | $1.25M | $4.08M | $-9.66M | $-32.92M | $-68.50M | $-123.90M | $-130.10M | $-218.02M | $-418.95M | $-383.58M | $-583.19M | $-481.45M | $-378.08M | $-219.03M |
| Net income growth (YoY) | — | +226.3% | -336.8% | -240.9% | -108.1% | -80.9% | -5.0% | -67.6% | -92.2% | +8.4% | -52.0% | +17.4% | +21.5% | +42.1% |
| Profit margin | 8.0% | 20.0% | -69.1% | -405.5% | -1487.3% | -8097.8% | -1229.5% | -1630.0% | -6025.5% | -4931.6% | -1139.6% | -180.5% | -104.0% | -31.7% |